The FDA database lists a supplement dated 13 October 2026 to abbreviated new drug application 207490 for buprenorphine, held by Strides Pharma. An abbreviated application covers a generic product.
The record does not state what the supplement changes. Supplements to generic applications commonly concern manufacturing, labelling alignment or packaging, and are administrative rather than a new safety finding or indication.
For anaesthetists, there is nothing here that changes perioperative management of patients on buprenorphine. Its availability in India is governed by CDSCO and the narcotic drug regulations, not by this FDA action.
- This is an FDA supplement to a generic buprenorphine application, not a new approval.
- The record does not describe the change.
- No new safety communication accompanies it.
- Perioperative handling of patients on buprenorphine is unchanged.
Why it matters
It shows the generic supply line is active, but carries no clinical signal.
Don't overread it
A supplement to a generic application is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for anaesthesiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free